Published On: Wed, Oct 19th, 2016

New Analyst Ratings On MEI Pharma, Inc. (MEIP)


Recently stock market analysts have updated their consensus ratings on shares of MEI Pharma, Inc. (MEIP).

Most recent broker ratings

08/03/2016 – MEI Pharma, Inc. had its “hold” rating reiterated by analysts at Wedbush. They now have a USD 2 price target on the stock.

10/07/2015 – MEI Pharma, Inc. had its “buy” rating reiterated by analysts at Cowen.

09/02/2015 – MEI Pharma, Inc. had its “buy” rating reiterated by analysts at Cantor Fitzgerald.

05/13/2015 – MEI Pharma, Inc. was downgraded to “hold” by analysts at Zacks. They now have a USD 6.3 price target on the stock.

03/24/2015 – MEI Pharma, Inc. was downgraded to “neutral” by analysts at Bank of America Merrill Lynch.

03/24/2015 – MEI Pharma, Inc. was downgraded to “market perform” by analysts at Wells Fargo.

03/23/2015 – MEI Pharma, Inc. was downgraded to “hold” by analysts at Stifel Nicolaus.

03/23/2015 – MEI Pharma, Inc. was downgraded to “neutral” by analysts at Roth Capital. They now have a USD 2.5 price target on the stock.

09/10/2014 – MEI Pharma, Inc. had its “buy” rating reiterated by analysts at Brean Capital. They now have a USD 16 price target on the stock.

MEI Pharma, Inc. has a 50 day moving average of 1.76 and a 200 day moving average of 1.56. The stock’s market capitalization is 59.94M, it has a 52-week low of 0.87 and a 52-week high of 2.28.

The share price of the company (MEIP) was up +1.24% during the last trading session, with a high of 1.64 and the volume of MEI Pharma, Inc. shares traded was 39563.

MEI Pharma, Inc. is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). ME-344 is an isoflavone-based mitochondrial inhibitor targeting a mitochondrial component of the terminal respiratory chain complex in rapidly proliferating cells. PWT143 is an oral inhibitor of phosphatidylinositide 3-kinase (PI3K) delta, a molecular target that plays a critical role in the proliferation and survival of hematologic cancer cells. Pracinostat has been tested in multiple Phase I and Phase II clinical trials in advanced hematologic malignancies and solid tumor indications.